INmune Bio files CORDStrom patent in U.S. after favorable PCT opinion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as Big Tech earnings rekindle AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
July 1, 2026 7:00 AM EDTSecures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045
BOCA RATON, Fla., July 01, 2026 (GLOBE NEWSWIRE) -- -- INmune Bio Inc. (NASDAQ: INMB) (the Company), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its CORDStrom platform patent application into the U.S. national phase before the United States Patent and Trademark Office (USPTO), advancing a key element of the Companys global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC)... More
